Mikhail Blagosklonny on Anti-Aging Drugs

Mikhail Blagosklonny on Anti-Aging Drugs

Many people believe that aging is brought about by consistent molecular damage with no means of prevention. Mikhail Blagosklonny who is a renowned scientist focusing on the study of aging and cancer gave a different account of this belief about aging. In the article, rejuvenating immunity aging is explained through hyperfunction theory. The theory holds that aging is simply a constant growth that is caused by signaling pathways which include Target of Rapamycin (TOR). The TOR models envisage that the rapamycin or any other rapalog has the capability to prevent diseases and treat aging in humans. Apparently so as to experience the full benefit from the rapamycin and other rapalogs, one needs to take the right doses and follow a regular schedule. Every theory faces acceptance, and some criticism and hyperfunction theory was not exceptional. However, in 2008, it was envisaged that those who opposed the theory by then, will take the TOR model for granted and this prediction came to happen.

A study was carried out on one of rapamycin analogs, Evirolimus (RAD001) and it was held that the analog is capable of improving immunity to the aging people. These were sensational news which said that the Novartis who were researching on ‘Fountain of Youth’ Drug might have found the drug that could help to delay the effects of an aging human being and also enhance their health. Nir Barzilai summarized the report saying that the research sets a standard stage to begin using drugs to target aging so as to improve every aspect of aging. He adds that the research is a turning point for many scientists. Visit ResearchGate to keep up to date with Mikhail’s latest work.

Looking into the history of rapamycin, it was in the year 2006 when Rapamune or Sirolimus which is a form of rapamycin, was approved to be used for clinical purposes. The drug was available, and apart from being believed to heal diseases such as cancer, autoimmunity, metabolic disorders and cardiovascular diseases, it was proven to heal diseases related to aging such as Alzheimer and osteoporosis. Rapamycin was expected to be rampantly used as an anti-aging drug to delay senescence and prevent illnesses as well. The drug is also recommended to be taken by transplant patients for some time so as to enhance their health. It is believed that rapamycin is capable of changing immunity of aging person from ‘aged-type’ to ‘infant type’ because instead of suppressing immunity, it eradicates hyper-immunity.

About Mikhail Blagosklonny

Mikhail Blagosklonny is a prominent scientist who specializes in the study of cancer and aging. He is currently an oncology professor at Roswell Park Cancer Institute where he has been serving since the year 2009. Mikhail Blagosklonny gained his MD in internal medicine and a Ph.D. in Experimental Medicine and Cardiology from First Pavlov State Medical University in St. Petersburg. In the year 2002, he joined New York Medical College where he became an associate professor of medicine and later he went to Ordway Research Institute serving as a senior scientist. Mikhail Blagosklonny managed to attain adequate experience from the different places he had worked for, and this made him a prominent professor who is mostly interested in anti-aging drugs, cancer, Biogerontology and cancer-related therapies. Check Mikhail’s profile in LinkedIn.

Leave a Reply

Your email address will not be published. Required fields are marked *